Compass Pathways Plc - ADR

+0.46 (+2.93%)
Earnings Announcements

Compass Pathways Announces Results From Phase IIB Trial Of Psilocybin Therapy For Depression

Published: 12/01/2021 12:37 GMT
Compass Pathways Plc - ADR (CMPS) - Compass Pathways Announces Further Positive Results From Groundbreaking Phase Iib Trial of Investigational Comp360 Psilocybin Therapy for Treatment-resistant Depression.compass Pathways Plc - Objective of Trial Was to Find Appropriate Dose for a Larger, Pivotal Phase Iii Programme, Which Compass Expects to Begin in 2022.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.50

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.52

More details on our Analysts Page.